All HHS Contracts — June 17, 2026

Leidos Holdings, Inc. won a $126.4M cost-plus-fixed-fee delivery order from the NIH National Cancer Institute to manage GOCO R&D facility space in Frederick, MD. The full-and-open competition and cost-plus structure indicate stable, low-risk revenue with $52.2M still obligated through August 2024.

Leidos' reliance on a single NIH NCI GOCO facility management contract for $126.4M in civilian R&D revenue creates concentration risk. The contract ends August 2024 with no options, and no follow-on award is yet visible.

NIH NCI budget appropriations for FY2024 and beyond are subject to congressional appropriations cycles and potential Continuing Resolutions, which could delay or reduce funding for follow-on contracts.

Leidos' proven performance on this GOCO facility contract positions it favorably for any follow-on award or expansion of NIH NCI R&D facility management services, potentially extending the revenue stream beyond August 2024.

The $126.4M award to Leidos for GOCO facility management underscores sustained NIH investment in cancer research infrastructure, even amid broader federal budget uncertainty. This contract is a civilian R&D support play, not defense-related.

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"The $126.4M NIH NCI contract ends August 2024 with no options; a follow-on award is critical to maintain revenue in Leidos' biomedical research segment.", "trigger"=>"Re-compete announcement or extension for GOCO facility management at Frederick, MD"}

{"entity"=>"NIH National Cancer Institute", "reason"=>"NCI budget appropriations directly impact the likelihood and timing of a follow-on contract for Leidos.", "trigger"=>"FY2024 NIH budget passage or CR resolution"}